Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2026-06-04 20:00:06 ET · period of report 2026-06-02 · accession 0002069239-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-04 20:00 | 2026-06-02 | JANX | Doyle Janeen Noel | Chief Corp, Bus. Dev. Ofcr | S - Sale | $14.03 | -4,059 | 75.9K | -5% | -$56.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-02 | S | D | 4,059 | $14.03 | 75,941 | D | — | — | (F1) The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. (F2) The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |